Health Technology Review Remove
CADTH’s health technology assessment report on long-acting beta2-agonist (LABA) and inhaled corticosteroid (ICS) combination therapy examines the clinical efficacy, safety, and cost-effectiveness of...
Context and Policy Issues Colorectal cancer (CRC) is the second leading cause of cancer-related deaths among men and women in Canada. Compared to no screening, screening for CRC is associated with a...
Context and Policy Issues Stereotactic radiosurgery (SRS) and stereotactic radiotherapy, which deliver high doses of radiation to tumour sites, are used to stop the division of tumour cells. Three...
Context and Policy Issues Venous thromboembolism (VTE) can lead to increased morbidity and mortality through the clinical manifestations of deep vein thrombosis (DVT) and pulmonary embolism (PE)...
In 2006, CADTH commissioned a study of the clinical efficacy and cost-effectiveness of drugs and therapies approved for use in Canada for people with neovascular age-related macular degeneration (AMD)...
The four-part CADTH health technology assessment series on Canadian emergency department (ED) overcrowding is the first national, comprehensive study of the issue. It is designed to help Canadian...
Technology Name Salmeterol (Serevent®) Formoterol (Foradil®) Technology Description Salmeterol and formoterol are bronchodilators administered by inhaler. Bronchodilators are used to treat people with...
Cite as: Otten N. Economic evaluation of erythropoietin use in surgery. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 1998. The Issue The use of allogeneic (donor)...
Cite as: Reeve J, Corabian P. Transcutaneous Electrical Nerve Stimulation (Tens)and Pain Management. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 1995. This report...